PEPTIDE GUIDE

What Is Melanotan I?

Melanotan I is an early name for afamelanotide, a synthetic 13-amino-acid analogue of alpha-melanocyte-stimulating hormone. It was designed to activate the melanocortin 1 receptor, usually shortened to MC1R, more strongly and for longer than the natural hormone.

The molecule is also called Nle4,D-Phe7-alpha-MSH or NDP-alpha-MSH. It can increase production of eumelanin, the brown-black form of melanin. That pigmentation effect led to early research on tanning and protection from light-related injury.

Afamelanotide later became the active ingredient in Scenesse, a regulated slow-release implant approved for a rare light-sensitivity disorder called erythropoietic protoporphyria. This creates an unusual but important situation: the active peptide historically called Melanotan I is an approved medicine in one exact product and indication, while unregulated vials or sprays sold as “Melanotan 1” are not approved Scenesse and have not inherited its quality, formulation, evidence or legal status.

Research statusAfamelanotide is approved only as a specified implant for defined EPP use
Compound typeLinear 13-amino-acid alpha-MSH analogue
Human evidenceRandomised trials and regulated use in EPP
ApprovalScenesse implant approved for defined EPP use
Last reviewed17 November 2026
THE SHORT ANSWER

Melanotan I and afamelanotide refer to the same 13-amino-acid melanocortin analogue, Nle4,D-Phe7-alpha-MSH. It activates MC1R and can increase eumelanin production. The FDA-approved and EU-authorised product Scenesse contains afamelanotide in a biodegradable subcutaneous implant for adults with erythropoietic protoporphyria. Approval does not extend to online Melanotan I injections, powders or nasal sprays, and it does not authorise cosmetic tanning use. Controlled trials in erythropoietic protoporphyria found increases in pain-free light exposure, but the benefit was measured in a rare disease and should not be converted into claims that tanning prevents ordinary ultraviolet damage or skin cancer. Pigmented lesions can darken, so regulated treatment includes skin monitoring.

What kind of molecule is Melanotan I?

Melanotan I is a linear peptide containing 13 amino-acid residues. Its sequence is based on alpha-MSH but includes two important substitutions: norleucine at position 4 and D-phenylalanine at position 7. These changes are represented by the name Nle4,D-Phe7-alpha-MSH.

Norleucine replaces a methionine found in natural alpha-MSH. D-phenylalanine uses the mirror-image configuration of the naturally common L-amino acid. Together, the substitutions increase resistance to enzymatic breakdown and strengthen melanocortin-receptor activity.

The peptide is acetylated at the N-terminus and amidated at the C-terminus, matching important terminal features of alpha-MSH. It remains linear rather than being cyclised like Melanotan II.

Small sequence changes can materially alter receptor potency, selectivity and duration. “Alpha-MSH analogue” therefore describes its origin, not equivalence to the natural hormone.

Are Melanotan I and afamelanotide the same thing?

At the molecular level, yes. Melanotan I was an early development name for the peptide later given the generic drug name afamelanotide. Both refer to Nle4,D-Phe7-alpha-MSH.

At the product level, no equivalence should be assumed. Scenesse is a specified biodegradable implant containing afamelanotide and excipients. It is manufactured, tested, packaged and administered under an approved system. An online vial carrying “Melanotan I” may claim the same sequence, but its identity, amount, impurities, sterility and stability are separate questions.

This is the central point for interpreting the subject. It is inaccurate to say that Melanotan I is a completely different active peptide from afamelanotide. It is equally inaccurate to say that any Melanotan I product is effectively Scenesse.

NameWhat it describesRegulatory meaning
Melanotan IHistorical development name for Nle4,D-Phe7-alpha-MSHDoes not approve products sold under this name
AfamelanotideGeneric name for the same active peptideApproval depends on the finished product and indication
ScenesseRegulated biodegradable afamelanotide implantApproved for defined EPP use in specified jurisdictions
Melanotan IIShorter cyclic melanocortin analogueSeparate molecule and not approved as a tanning medicine

What is alpha-melanocyte-stimulating hormone?

Alpha-MSH is a naturally occurring 13-amino-acid peptide derived from a larger precursor protein called proopiomelanocortin, or POMC. Processing of POMC also produces other biologically active peptides in different tissues.

Alpha-MSH can activate melanocortin receptors. MC1R on melanocytes is particularly important for pigmentation. When activated, it increases cyclic AMP signalling and promotes enzymes involved in melanin synthesis.

Natural alpha-MSH is rapidly broken down and is not an efficient long-acting medicine. Afamelanotide was designed to retain the 13-residue framework while increasing potency and stability.

Alpha-MSH biology extends beyond pigmentation. Melanocortin signalling participates in inflammation, energy balance and other physiological processes. Afamelanotide is relatively focused on MC1R compared with less selective analogues, but no receptor agonist should be described as acting in a perfectly isolated pathway.

What is the melanocortin receptor system?

Five melanocortin receptors are recognised, MC1R through MC5R. They are G-protein-coupled receptors with different tissue distributions and physiological roles.

ReceptorCommonly associated biology
MC1RPigmentation, melanocyte signalling and aspects of inflammation
MC2RAdrenal response to adrenocorticotropic hormone
MC3REnergy balance and central melanocortin signalling
MC4RAppetite, body weight and autonomic functions
MC5RExocrine and other peripheral functions

Afamelanotide’s pigmentation effect is mainly attributed to MC1R activation. Melanotan II has broader melanocortin activity and is more strongly associated with appetite and sexual effects. This pharmacological difference helps explain why the two compounds followed different development paths.

How does MC1R signalling change pigmentation?

Melanocytes make melanin and transfer pigment-containing organelles to keratinocytes in the surrounding epidermis. MC1R activation increases cyclic AMP and promotes activity of transcription factors and enzymes including tyrosinase.

Human melanin is commonly discussed as eumelanin and pheomelanin. Eumelanin is brown-black and absorbs ultraviolet radiation more effectively. Pheomelanin is red-yellow and offers less photoprotection. MC1R signalling tends to favour eumelanin production.

MC1R variants contribute to differences in hair colour, skin response and tanning ability. Some variants associated with red hair and fair skin respond less efficiently to natural alpha-MSH signalling. Afamelanotide can still increase pigmentation in some people, but response is not identical across genotypes or skin types.

A drug-induced increase in pigmentation is not the same as complete protection from ultraviolet radiation. DNA damage can still occur, and sunscreen, clothing, shade and medical advice remain relevant.

What is the difference between pigmentation and photoprotection?

Pigmentation is a visible biological response. Photoprotection is the reduction of tissue injury from particular wavelengths and exposure conditions. The two overlap but are not interchangeable.

Eumelanin can absorb and scatter ultraviolet radiation and can help neutralise reactive chemical species. A darker epidermis may therefore reduce some ultraviolet penetration compared with the same skin before pigmentation. It does not create an impenetrable shield.

Sunlight contains ultraviolet A, ultraviolet B and visible wavelengths. EPP reactions are driven largely by visible light around the absorption spectrum of accumulated protoporphyrin. Ordinary sunburn and much skin-cancer risk relate strongly to ultraviolet exposure. An intervention can improve tolerance of one phototoxic mechanism without cancelling another.

This is why “sunless tan” and “sun protection” should not be treated as synonyms. A cosmetic colour change is not a validated sun-protection factor, and it cannot be used to calculate safe exposure time.

How was Melanotan I developed?

Researchers at the University of Arizona investigated more potent alpha-MSH analogues during the 1980s. The original goal was to produce pigmentation without requiring as much ultraviolet exposure. NDP-alpha-MSH showed stronger and longer melanotropic activity than the natural peptide.

Early human work used repeated subcutaneous administration to study pharmacokinetics and pigmentation. The name “Melanotan” emerged during this tanning-focused phase. A separate shorter cyclic analogue became Melanotan II.

Development of the linear analogue shifted towards medical photoprotection. The molecule was renamed afamelanotide, and a biodegradable implant formulation was created to provide controlled release. European authorisation for Scenesse followed in 2014, and FDA approval followed in 2019 for a defined adult EPP indication.

PeriodDevelopment
1980sPotent alpha-MSH analogues including NDP-alpha-MSH were developed
1990sHuman pigmentation and pharmacokinetic research expanded
2000sImplant development focused increasingly on photodermatoses
2014The EU authorised Scenesse for erythropoietic protoporphyria
2019The FDA approved Scenesse for adults with EPP and a history of phototoxic reactions
2026EPP use remains established while vitiligo and other uses continue to be investigated

What is erythropoietic protoporphyria?

Erythropoietic protoporphyria, or EPP, is a rare inherited disorder of haem synthesis. Protoporphyrin accumulates, particularly in red blood cells and tissues. Exposure to visible light can activate the accumulated molecule and generate tissue injury.

People with EPP can experience severe burning pain, swelling and redness after brief light exposure. Symptoms may occur without the kind of obvious sunburn that other people recognise. This can profoundly restrict outdoor activity, education, work and social life.

EPP is not ordinary photosensitivity and the Scenesse indication is not cosmetic tanning. The treatment goal is to increase pain-free light exposure and reduce the burden of phototoxic reactions in a medically diagnosed population.

EPP can also affect the liver in some people because protoporphyrin is cleared through bile. Afamelanotide addresses phototoxic symptoms rather than correcting the underlying genetic defect or removing all systemic risk.

What did the pivotal EPP trials find?

Randomised placebo-controlled trials in Europe and the United States evaluated afamelanotide implants in people with EPP. The main publication reported longer pain-free time in direct sunlight and improved quality-of-life measures, alongside fewer or less burdensome phototoxic reactions under some analyses.

The absolute difference in recorded sunlight time was not enormous, partly because participants had learned over many years to avoid exposure and because environmental light varies. Measuring benefit in EPP is difficult: deliberate exposure can cause extreme pain, so a conventional challenge test would be ethically problematic.

Trial outcomes therefore combined participant-recorded exposure, pain and quality-of-life information. The findings supported regulatory approval, but they do not show that users can tolerate unlimited sun or stop protective behaviour.

Real-world studies often report larger perceived benefits than pivotal trials. Observational data can capture ordinary life over longer periods, but they are more vulnerable to selection, expectation and missing-data bias. Both trial and real-world evidence contribute different information.

What exactly is Scenesse?

Scenesse is a sterile implant containing afamelanotide within a biodegradable polymer matrix. The US label specifies 16 mg of afamelanotide in each implant. Trained healthcare professionals insert the implant subcutaneously using a defined procedure.

The polymer controls release as it degrades. This is very different from dissolving peptide powder for injection or using a nasal spray. A controlled-release implant changes peak concentration, duration and total exposure.

The product label defines eligible patients, administration, adverse reactions and skin monitoring. Approval attaches to this complete medicine rather than to the word afamelanotide in isolation.

The implant is not approved in the United States for cosmetic tanning, ordinary sun protection, vitiligo or prevention of skin cancer. Indications vary between regulators and should be checked in the current local product information.

What adverse effects are listed for regulated afamelanotide?

The US prescribing information identifies implant-site reactions, nausea, oropharyngeal pain, cough, fatigue, dizziness, somnolence, increased pigmentation and darkening of existing moles or freckles among reported reactions.

Skin pigmentation is an intended pharmacological effect, but changes can complicate observation of pigmented lesions. The label recommends full-body skin examinations before and during treatment.

The clinical-trial population was limited because EPP is rare. Regulators continue pharmacovigilance after approval to identify uncommon or delayed events that trials may not detect.

These data apply to Scenesse used in its approved context. An unregulated product adds risks from unknown content, contamination, formulation and administration that are not captured by the label.

Afamelanotide can darken existing naevi, commonly called moles, and ephelides, commonly called freckles. That is compatible with its pharmacology, but a changing pigmented lesion can also be a warning sign requiring assessment.

The US label advises full-body skin examinations before and during treatment. Monitoring is not an admission that afamelanotide has been proven to cause melanoma. It is a precaution that recognises both the expected pigmentary effect and the importance of detecting skin cancer early.

Clinical examination considers asymmetry, border, colour, diameter, evolution and the wider pattern of a person’s lesions. A photograph taken for cosmetic comparison cannot substitute for professional dermoscopic assessment when a lesion changes.

Unsupervised users may darken multiple lesions without baseline documentation or follow-up. This makes it harder to distinguish an expected pigmentary change from a lesion that needs investigation.

Does afamelanotide prevent skin cancer?

There is no approved general claim that afamelanotide prevents melanoma or other skin cancers. Eumelanin can absorb ultraviolet radiation and support photoprotective processes, but increasing pigmentation does not eliminate DNA damage.

EPP phototoxicity arises mainly from visible-light activation of protoporphyrin, not from the same mechanism as ordinary ultraviolet sunburn. A medicine improving EPP light tolerance therefore cannot be assumed to prevent ultraviolet carcinogenesis in the general population.

People may spend more time outdoors when symptoms improve. That makes ordinary sun-protection advice and skin surveillance important. A darker appearance should not be used as a signal that exposure is safe.

What has been studied in vitiligo?

Vitiligo involves loss of functioning melanocytes in affected skin. Afamelanotide has been studied alongside narrowband ultraviolet B phototherapy to see whether melanocortin stimulation accelerates repigmentation.

A randomised multicentre trial enrolled 55 adults with nonsegmental vitiligo. Combination treatment produced faster and greater repigmentation than phototherapy alone in some body regions and skin phototypes. The study was relatively small and did not establish a general approved indication.

Current trials continue to examine the approach. Vitiligo varies in extent, activity, skin type and response to treatment. Evidence for supervised combination therapy should not be converted into claims for cosmetic self-use.

What other conditions have been investigated?

Researchers have explored afamelanotide in other photodermatoses and pigmentary disorders. Examples include solar urticaria and selected forms of phototoxicity. Evidence varies from early studies to development programmes.

The molecule’s anti-inflammatory and melanocortin biology has generated broader hypotheses, but receptor activity and laboratory findings do not establish clinical effectiveness. Each condition requires its own controlled evidence.

An approved EPP medicine is sometimes used rhetorically to make the compound sound broadly proven. The accurate statement is narrower: a specific implant has demonstrated a sufficient benefit-risk balance for a specific rare disease.

What did Health Canada's November 2026 peptide contamination warning find?

On 12 November 2026, Health Canada reported that laboratory testing had identified *Sphingomonas aquatilis/melonis* bacteria in an injectable peptide product seized from a retailer in Ottawa. The retailer's unauthorised inventory included products labelled Melanotan I. The agency did not say that every product on its inventory list, or every batch of the named compound, tested positive for bacteria.

This is a product-quality and safety finding, not a new clinical trial of the peptide. Bacterial contamination in material intended for injection can cause serious infection, including sepsis. The agency also warned that a label saying 'for research use only' does not demonstrate sterility or make an unauthorised product suitable for human use. The finding cannot be used to estimate contamination rates across the wider market or to judge the quality of material used in controlled clinical studies.

Is Melanotan I an approved tanning peptide?

No. Afamelanotide is approved in Scenesse for EPP, not for cosmetic tanning. Regulators have not approved generic online Melanotan I injections, powders or nasal sprays as substitutes.

Calling an online product “afamelanotide” does not prove it contains the approved active sequence or amount. Even if the sequence were correct, a bolus injection and a controlled-release implant can create different exposure profiles.

Cosmetic tanning claims also encourage a misleading risk calculation. A peptide-induced tan does not make deliberate ultraviolet exposure harmless. Product uncertainty and unsupervised administration add risks without the clinical justification present in EPP.

Why can online products not rely on the Scenesse trials?

The Scenesse evidence package links a known active substance to a particular implant, polymer, release profile, manufacturing system and clinical indication. Trial participants received that controlled intervention and were monitored under a protocol.

An online powder or nasal spray changes several variables at once. It may use a different salt or formulation, create a different concentration-time profile and lack verified sterility or content. The seller may not demonstrate that the labelled sequence is present at all.

Even a laboratory result showing the expected molecular mass would not establish equivalence. It would not fully characterise related impurities, biological potency, release kinetics or clinical safety.

Evidence belongs to the tested intervention. Sharing a claimed ingredient name is not enough to borrow the conclusions of an approved product’s trials.

How is afamelanotide manufactured?

Afamelanotide can be made using solid-phase peptide synthesis. Protected amino acids are coupled step by step while the chain remains attached to a resin. The two non-natural substitutions and terminal modifications must be incorporated in the correct positions.

After cleavage and deprotection, the crude peptide can contain deletion sequences, incompletely coupled chains, stereochemical errors, oxidation products and residual reagents. Preparative chromatography is commonly used to purify the active substance.

Identity may be assessed with mass spectrometry, peptide mapping and chromatographic comparison. Specifications can also address peptide content, related substances, counterions, residual solvents, water and biological potency.

Making Scenesse requires a further controlled process. The peptide is incorporated into a biodegradable implant with defined release characteristics. Sterility, endotoxins, implant dimensions, content uniformity, polymer quality, packaging and stability all need validation.

A seller’s HPLC purity percentage addresses only part of this chain. It does not show correct stereochemistry, sterile manufacture, accurate vial content or equivalence to the implant.

What affects stability and product quality?

Peptides can degrade through oxidation, hydrolysis, deamidation and other chemical pathways. Afamelanotide replaces oxidation-prone methionine with norleucine, improving stability relative to natural alpha-MSH, but it is not indestructible.

Temperature, moisture, oxygen, light, buffer composition and contact surfaces can affect a formulation. Stability data belong to an exact product in its exact container. Instructions copied from a different formulation do not validate an online vial.

Unregulated products present an upstream problem: storage cannot correct uncertain synthesis, contamination or mislabelling. A product kept cold from delivery may already have been degraded or incorrectly manufactured.

How does Melanotan I differ from Melanotan II?

FeatureMelanotan I / afamelanotideMelanotan II
StructureLinear 13-amino-acid alpha-MSH analogueShorter cyclic melanocortin analogue
Main development focusPhotoprotection and pigmentationPigmentation and central melanocortin effects
Receptor profileGreater emphasis on MC1RBroader melanocortin-receptor activity
Approved productScenesse implant for defined EPP useNo approved Melanotan II medicine
Notable effectsPigmentation and improved light tolerance in EPPPigmentation, nausea, appetite and sexual effects in small studies

The names make the compounds sound like versions of the same consumer product, but their structures, receptor activity and regulatory histories differ. Neither name authorises an online tanning product.

Does Melanotan I suppress appetite or affect sexual function?

Afamelanotide was designed primarily around MC1R-mediated pigmentation. It is less associated with MC3R and MC4R effects than Melanotan II. Appetite suppression, yawning and spontaneous erections are more characteristic of Melanotan II’s early human research.

This does not mean afamelanotide can never have systemic effects. It means evidence from Melanotan II should not be transferred to Melanotan I because both belong to the melanocortin family.

Commercial claims often blur the two names or sell mixed expectations involving tanning, weight and sexual effects. Accurate identification of the molecule is the first requirement for interpreting any claim.

What remains unknown?

Long-term regulated evidence remains limited by the rarity of EPP. Ongoing surveillance is needed for uncommon adverse effects, changes in pigmented lesions and outcomes after many years of treatment.

Investigational uses such as vitiligo require larger trials and regulatory review. A faster pigment response is not automatically a durable improvement across all skin types or disease patterns.

The greatest uncertainty around online Melanotan I is often the product itself. Without independent identity, content, impurity, sterility and stability data, pharmacological discussion cannot establish what exposure occurred.

What would stronger evidence for broader use require?

For a new indication, researchers would need a defined formulation, appropriate comparator and outcomes that matter to patients. A pigmentation score alone would not be enough if the intended claim concerned pain, daily function, disease progression or cancer prevention.

Trials would need adequate duration to examine whether benefit persists and whether increased light exposure introduces other risks. Skin type, MC1R genotype, baseline lesions and ordinary sun behaviour could modify outcomes.

Cosmetic use would still require a favourable benefit-risk assessment. The willingness to accept uncertainty is different when treating a disabling rare disease and when changing appearance in a healthy person.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

Is Melanotan I the same molecule as afamelanotide?

Yes. Melanotan I was an early name for Nle4,D-Phe7-alpha-MSH, now called afamelanotide.

Is Melanotan I the same product as Scenesse?

No. Scenesse is a regulated biodegradable afamelanotide implant. A vial or spray sold as Melanotan I is not automatically equivalent.

Is Melanotan I a peptide?

Yes. It is a synthetic linear peptide containing 13 amino-acid residues.

What receptor does it activate?

Its pigmentation effects are mainly mediated through MC1R.

Why was it modified from natural alpha-MSH?

The norleucine and D-phenylalanine substitutions increase stability and melanocortin activity.

Is afamelanotide FDA approved?

Scenesse was FDA approved in 2019 for adults with EPP and a history of phototoxic reactions.

Is it authorised in Europe?

Yes. Scenesse has EU authorisation for a defined EPP population, subject to the current product information.

Is it approved for cosmetic tanning?

No.

Does the approval make online Melanotan I legal or medically equivalent?

No. Approval applies to the specified finished medicine, manufacturer, formulation and indication.

Does it protect completely against sunlight?

No. EPP patients still require clinical guidance, and pigmentation does not eliminate ultraviolet damage.

Does it prevent skin cancer?

No general preventive indication has been established.

Can it darken moles and freckles?

Yes. Increased pigmentation of existing lesions is recognised, which is why regulated treatment includes skin monitoring.

Has it been studied for vitiligo?

Yes. Trials have examined afamelanotide implants combined with narrowband UV-B, but this is separate from the approved EPP indication.

Is Melanotan I safer than Melanotan II?

The compounds differ, and Scenesse has a regulated evidence package. That does not establish the safety of unregulated Melanotan I products.

Are study amounts instructions for tanning use?

No. Clinical study and label information describe supervised research or approved care, not self-administration.

RESEARCH AND MEDICAL NOTICE

This guide explains afamelanotide biology, regulated Scenesse evidence and product-quality limitations. It does not recommend cosmetic tanning, provide administration instructions or treat online Melanotan I products as approved medicines.

Research reviewed through 17 November 2026.